Design Therapeutics Total Debt vs. Cash Per Share
| DSGN Stock | USD 5.62 0.05 0.90% |
For Design Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Design Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Design Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Design Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Design Therapeutics over time as well as its relative position and ranking within its peers.
Design |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Design Therapeutics Cash Per Share vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Design Therapeutics's current stock value. Our valuation model uses many indicators to compare Design Therapeutics value to that of its competitors to determine the firm's financial worth. Design Therapeutics is rated below average in total debt category among its peers. It is rated below average in cash per share category among its peers . The ratio of Total Debt to Cash Per Share for Design Therapeutics is about 472,868 . At this time, Design Therapeutics' Cash Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Design Therapeutics' earnings, one of the primary drivers of an investment's value.Design Total Debt vs. Competition
Design Therapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 737.28 Million. Design Therapeutics adds roughly 3.05 Million in total debt claiming only tiny portion of equities under Health Care industry.
Design Cash Per Share vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Design Therapeutics |
| = | 3.05 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Design Therapeutics |
| = | 6.45 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Design Cash Per Share Comparison
Design Therapeutics is currently under evaluation in cash per share category among its peers.
Design Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Design Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Design Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Design Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Design Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 62 K | 65.1 K | |
| Operating Income | -78.2 M | -74.3 M | |
| Net Loss | -72.4 M | -68.7 M | |
| Income Before Tax | -66.9 M | -63.5 M | |
| Total Other Income Expense Net | 11.3 M | 11.9 M | |
| Net Loss | -57 M | -54.1 M | |
| Net Loss | -66.9 M | -63.5 M | |
| Income Tax Expense | (1.00) | (1.05) | |
| Non Operating Income Net Other | 4.9 M | 2.5 M | |
| Change To Netincome | 12.6 M | 13.2 M | |
| Net Loss | (1.19) | (1.25) | |
| Income Quality | 0.88 | 0.58 | |
| Net Income Per E B T | 0.83 | 0.74 |
Design Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Design Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Design Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Design Therapeutics' important profitability drivers and their relationship over time.
Use Design Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Design Therapeutics Pair Trading
Design Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Design Therapeutics position
In addition to having Design Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Penny Thematic Idea Now
Penny
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
To fully project Design Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Design Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Design Therapeutics' income statement, its balance sheet, and the statement of cash flows.